Trial reportTrials2026
Efficacy and safety of remimazolam for sedation of patients with end-stage renal disease: a prospective, randomized controlled clinical trial.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProcedural sedation in patients with end-stage renal disease (ESRD) is challenging due to impaired renal function, which affects drug metabolism and increases the risk of adverse events. Remimazolam, a novel ultrashort-acting intravenous sedative, offers rapid onset and clearance independent of renal function, making it a potential alternative to dexmedetomidine for sedation in this patient population. This study aims to compare the efficacy and safety of remimazolam versus dexmedetomidine in ESRD patients undergoing procedural sedation. The primary hypothesis is that remimazolam will demonstrate superior sedation efficacy and a better safety profile, with reduced hemodynamic instability and faster recovery.
methodsThis is a single-center, prospective, observer-blinded, randomized controlled trial (RCT). A total of 80 ESRD patients aged ≥ 18 years scheduled for peritoneal dialysis catheter placement or removal will be randomly assigned to receive either remimazolam or dexmedetomidine. The primary outcome is the sedation success rate, defined as achieving a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤ 1 within 10 min of drug administration. Secondary outcomes include time to sedation, intraoperative movements, the duration of BIS values < 60 or > 80 during anesthesia maintenance, recovery time, the incidence of adverse events, incidence of postoperative nausea and vomiting (PONV), and postoperative pain scores. DISCUSSION: This is the first RCT to directly compare remimazolam and dexmedetomidine for sedation in ESRD patients undergoing procedural sedation. The results of this study will provide valuable insights into optimizing sedation strategies in this high-risk population, potentially improving clinical outcomes by minimizing complications associated with drug metabolism and recovery.
trial registrationChinese Clinical Trial Registry. chictr.org.cn ChiCTR2300075278. Registered on August 31, 2023. https://www.chictr.org.cn/showproj.html?proj=205061 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.